Immunome, Inc. (IMNM)
- Previous Close
9.79 - Open
9.47 - Bid 9.15 x 100
- Ask 9.26 x 100
- Day's Range
9.02 - 9.82 - 52 Week Range
5.15 - 16.81 - Volume
1,247,688 - Avg. Volume
1,163,922 - Market Cap (intraday)
800.513M - Beta (5Y Monthly) 1.95
- PE Ratio (TTM)
-- - EPS (TTM)
-3.01 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.50
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
immunome.comRecent News: IMNM
View MorePerformance Overview: IMNM
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMNM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMNM
View MoreValuation Measures
Market Cap
800.51M
Enterprise Value
487.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
55.18
Price/Book (mrq)
2.61
Enterprise Value/Revenue
44.61
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.54%
Return on Equity (ttm)
-69.21%
Revenue (ttm)
10.94M
Net Income Avi to Common (ttm)
-205.11M
Diluted EPS (ttm)
-3.01
Balance Sheet and Cash Flow
Total Cash (mrq)
317.32M
Total Debt/Equity (mrq)
1.55%
Levered Free Cash Flow (ttm)
-117.16M